- Went public, Apr 2007
- Raised $10M pipe, Jan 2025
- Raised $9M pipe led by Highbridge Capital Management, Nov 2024
About
BioLineRx is a clinical-stage biopharmaceutical company focused on oncology. The company's pipeline currently consists of BL-8040, a platform for multiple cancer and hematological indications; and AGI-134, a synthetic immunotherapy in development for solid tumors.
The BioLineRx pipeline is generated by systematically identifying, validating, and in-licensing therapeutic candidates with advantages over current therapies or that address unmet medical needs.
BioLineRx also works with Novartis on the codevelopment of selected Israel-sourced novel drug candidates and has recently signed a collaboration agreement with MSD (known as Merck in the United States and Canada) to run a phase-2a study in pancreatic cancer using a combination of BL-8040 and Merck's Keytruda.
BioLineRx has received the FDA biological product designation for its novel cancer immunotherapy candidate AGI-134. In January 2020, the company announced that the European Commission had granted orphan drug designation to its lead oncology candidate, Motixafortide (BL-8040), for the treatment of pancreatic cancer.
Funding history · 12 rounds · $208.6M total
Q&A
- What is BioLineRx's primary focus as a biopharmaceutical company?
- BioLineRx is a clinical-stage biopharmaceutical company primarily focused on oncology, developing therapeutic candidates for various cancer and hematological indications.
- When did BioLineRx go public on the NASDAQ?
- BioLineRx went public on NASDAQ in March 2014, raising $21,000,000 through a public offering.
- Which company did BioLineRx acquire and when?
- BioLineRx acquired Agalimmune in March 2017 for $6,000,000.
- What is the status of BioLineRx's lead oncology candidate, Motixafortide (BL-8040), in Europe?
- In January 2020, the European Commission granted orphan drug designation to BioLineRx's lead oncology candidate, Motixafortide (BL-8040), for the treatment of pancreatic cancer.
- Who are the key executives at BioLineRx?
- The key executives at BioLineRx are Phil Serlin, CEO, and Mali Zeevi, CFO.
- How many employees does BioLineRx currently have?
- BioLineRx has 51–200 employees.
- When did BioLineRx last raise debt financing and from whom?
- In April 2024, BioLineRx raised $20,000,000 in debt financing from Kreos Capital.
- What was BioLineRx's most recent funding round?
- BioLineRx's most recent funding round was a pipe round in January 2025, raising $10,000,000.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | biolinerx.com |
|---|---|
| linkedin.com/company/112275 | |
| facebook.com/BioLineRx-786986118113858 | |
| YouTube | youtube.com/channel/UCjC1p4AbGeSzk1MjVaTEbAQ |
Identifiers & details
| Founded | 2003-4 |
|---|---|
| Employees (exact) | 54 |
| Market cap | $13.1M |
| Status reason | Public on TASE on Apr, 2007;Public on NASDAQ on Mar, 2014; |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| 2017-03 | $6.0M |
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2007-04 | ||||
| 2014-03 | $21.0M | |||
| 2015-03 | $25.0M | |||
| 2017-04 | $28.8M | |||
| 2019-02 | $15.4M | |||
| 2021-01 | $34.5M |